Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte Corporation runs a biopharmaceutical business with several commercialized products. The company does not only envisage that Jakafi may bring close to $3 billion in peak sales. Monjuvi is also expected to report $500-$750 million in sales.

Incyte's Increase In Jakafi's Sales Guidance Implies 29% Upside In The Valuation

Eli Lilly

INDIANAPOLIS, Nov. 9, 2021 /PRNewswire/ -- OLUMIANT ® (baricitinib) maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received OLUMIANT for 14,744 patient years of exposure, in line with previously published findings. Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021.

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

Amgen

Biogen

Gilead Sciences

Regeneron Pharmaceuticals

Biotech stocks have been picking up steam lately and several positive catalysts could keep the wind at the industry's back. Here are five names analysts are bullish on right now.

5 Buy-Rated Biotech Stocks to Bolster Your Portfolio

HOUSTON and SHANGHAI, Nov. 4, 2021 /PRNewswire/ -- Cellenkos ®  Inc. ("Cellenkos"), a biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders, today announced the close of $15 million Series A financing led by BVCF Management Ltd ("BVCF"). Proceeds from this financing will be used to further its development on the Treg cell therapy platform to address high unmet needs in autoimmune and inflammatory disorders.

Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH21--More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition.

More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

Incyte Corporation (INCY) CEO Herve Hoppenot on Q3 2021 results - Earnings Call Transcript

Incyte (INCY) beats earnings and sales estimates in the third quarter on higher royalty revenues and increased Jakafi sales.

Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow

Incyte (INCY) delivered earnings and revenue surprises of 55.26% and 8.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q3 Earnings and Revenues Beat Estimates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Parsaclisib is an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ).

Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

Incyte Corporation (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Incyte Corporation (INCY) Ahead of Earnings?

Incyte's (INCY) third-quarter 2021 earnings are likely to have gained from higher Jakafi sales as patients resume visits to the doctors.

Will Higher Jakafi Sales Boost Incyte's (INCY) Q3 Earnings?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

It's much too early to count these companies out.

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Incyte (INCY)

Viatris

A screening of healthcare stocks in the S&P 500 reveals that investors may find plenty of upside in three members of the index, according to an article in Barron's. The analysis showed that Vertex Pharmaceuticals ( VRTX , Financial), Viatris Inc. ( VTRS , Financial) and Incyte Corp. ( INCY , Financial) all sell at deep discounts to price forecasts by Wall Street analysts.

There's Money to Be Made With Vertex, Viatris, Incyte and Biogen

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADVCongress--Incyte Announces Full Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients with Vitiligo

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

Genmab - ADR

Seagen

Takeda Pharmaceutical

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NMEs, were approved in September.

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT® (baricitinib) 4-mg was superior to placebo in achieving significant scalp hair regrowth as early as 24 weeks in adults with severe alopecia areata (AA) as defined by ≥50% scalp hair loss at baseline.

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

Syndax Pharmaceuticals

Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.

Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize Syndax's axatilimab. Related Content:   Syndax Pharma Receives FDA Orphan Drug Designation For Axatilimab For Treatment Of Chronic Graft vs.

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate

Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases

News for Incyte Stock (INCY)